EANS-News: SYGNIS Pharma AG
Shareholders support management proposals at
SYGNIS Pharma´s AGM with overwhelming majority
25.11.2011 – 15:20
-------------------------------------------------------------------------------- Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. -------------------------------------------------------------------------------- Annual & Special Corporate Meetings Heidelberg (euro adhoc) - Shareholders support management proposals at SYGNIS Pharma´s AGM with overwhelming majority Heidelberg, 25 November 2011 - At today´s Annual General Meeting (AGM) of SYGNIS Pharma AG (Frankfurt: LIOK; ISIN DE000A1E9B74; Prime Standard) shareholders representing about 73 percent of the capital approved all proposals of the Management with an overwhelming majority. Main decisions were related to the discharge of the members of the Supervisory and the Management Board for the past Fiscal Year, the election of the members of the Supervisory Board as well as the creation of contingent capital for convertible bonds. All members of the Supervisory Board have been re-elected, with the exception of Mr. Friedrich Christ. Mr. Christ has meanwhile retired and it was his personal decision not to stand for re-election. From today´s AGM onwards, Dr. Wolf-Dieter Starp, Head of Global M&A at BASF SE, has been elected to the Supervisory Board. Prof. Dr. Friedrich von Bohlen und Halbach, chairman of the Supervisory Board thanked Mr. Christ for his work and efforts during the last years for SYGNIS Pharma AG. He welcomed Dr. Starp as a new member of the Supervisory Board. At the AGM the two members of the Management Board, Peter Willinger and Dr. Frank Rathgeb, confirmed that the data on SYGNIS´ current AXIS 2 efficacy study for AX200 for the treatment of acute stroke is expected to be published in December 2011. About SYGNIS Pharma SYGNIS Pharma AG, headquartered in Heidelberg, is a specialty pharmaceutical company listed on the Prime Standard of the German stock exchange. The Company is focused on the research, development and marketing of innovative therapies for the treatment of disorders of the Central Nervous System. These include Stroke, Amyotrophic Lateral Sclerosis and neurological disorders resulting from injuries to the brain or spinal cord. All these disorders are characterized by the fact that, as the disease progresses, nerve cells are damaged and die. Although there is great medical demand, there are currently no or only inadequate treatment options available. For further information please contact: SYGNIS Pharma AG: |Dr. Franz-Werner Haas | |Senior Vice President Operations | |+49 (0) 6221 454 812 | |franz-werner.haas@sygnis.de | Media-Contact: Julia Phillips FTI Consulting Tel.: +44 (0) 20 7269 7187 ### Disclaimer Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward- looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of SYGNIS Pharma AG may deviate greatly from the established conclusions or implied predictions contained in such statements. SYGNIS does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason. ### Further inquiry note: Michael Wolf Telefon: +49 (6221) 454 - 6 E-Mail: Michael.Wolf@sygnis.de end of announcement euro adhoc -------------------------------------------------------------------------------- company: SYGNIS Pharma AG Im Neuenheimer Feld 515 D-69120 Heidelberg phone: +49 (0)6221 454-6 FAX: +49 (0)6221 454-777 mail: contact@sygnis.de WWW: http://www.sygnis.de sector: Biotechnology ISIN: DE000A1E9B74 indexes: CDAX, Prime All Share stockmarkets: regulated dealing/prime standard: Frankfurt, free trade: Berlin, Hamburg, Stuttgart, Düsseldorf, Hannover, München language: English